Plasma adiponectin before and after kidney transplantation

Transplant International

Volumn 25, Issue 11, 2012, Pages 1194-1203

  Idorn, Thomas ^a   Hornum, Mads ^a   Bjerre, Mette ^b   Jørgensen, Kaj Anker ^c   Nielsen, Finn Thomsen ^d   Hansen, Jesper Melchior ^e   Flyvbjerg, Allan ^b   Feldt Rasmussen, Bo ^a  

^a Rigshospitalet   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

adiponectin; end stage renal disease; kidney transplantation; new onset diabetes mellitus

Indexed keywords

ADIPONECTIN;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE TOLERANCE; GRAFT RECIPIENT; HUMAN; INSULIN SENSITIVITY; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; UREMIA;

ADIPONECTIN; ADULT; DIABETES MELLITUS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INSULIN RESISTANCE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; UREMIA;

EID: 84867489376     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2012.01560.x     Document Type: Article

References (36)

1. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473.
2. Tschritter O, Fritsche A, Thamer C, et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 2003; 52: 239.
3. Spranger J, Kroke A, Mohlig M, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003; 361: 226.
4. Hara K, Horikoshi M, Yamauchi T, et al. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 2006; 29: 1357.
5. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930.
6. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595.
7. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79.
8. Yang WS, Lee WJ, Funahashi T, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001; 86: 3815.
9. Kobayashi H, Ouchi N, Kihara S, et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 2004; 94: e27-e31.
10. Otsuka F, Sugiyama S, Kojima S, et al. Plasma adiponectin levels are associated with coronary lesion complexity in men with coronary artery disease. J Am Coll Cardiol 2006; 48: 1155.
11. Zoccali C, Mallamaci F, Tripepi G, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 134.
12. Becker B, Kronenberg F, Kielstein JT, et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol 2005; 16: 1091.
13. Iwashima Y, Horio T, Kumada M, et al. Adiponectin and renal function, and implication as a risk of cardiovascular disease. Am J Cardiol 2006; 98: 1603.
14. Ix JH, Sharma K,. Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. J Am Soc Nephrol 2010; 21: 406.
15. Yaturu S, Reddy RD, Rains J, Jain SK,. Plasma and urine levels of resistin and adiponectin in chronic kidney disease. Cytokine 2007; 37: 1.
16. Lo MM, Mitsnefes M,. Adiponectin, cardiovascular disease, chronic kidney disease: emerging data on complex interactions. Pediatr Nephrol 2012; 27: 521.
17. Saraheimo M, Forsblom C, Fagerudd J, et al. Serum adiponectin is increased in type 1 diabetic patients with nephropathy. Diabetes Care 2005; 28: 1410.
18. Zoccali C, Mallamaci F, Panuccio V, et al. Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. Kidney Int Suppl 2003; 84: S98.
19. Guebre-Egziabher F, Bernhard J, Funahashi T, Hadj-Aissa A, Fouque D,. Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrol Dial Transplant 2005; 20: 129.
20. Chudek J, Adamczak M, Karkoszka H, et al. Plasma adiponectin concentration before and after successful kidney transplantation. Transplant Proc 2003; 35: 2186.
21. Taherimahmoudi M, Ahmadi H, Mehrsai A, Pourmand G,. Plasma adiponectin concentration and insulin resistance: role of successful kidney transplantation. Transplant Proc 2010; 42: 797.
22. Shen YY, Charlesworth JA, Kelly JJ, Peake PW,. The effect of renal transplantation on adiponectin and its isoforms and receptors. Metabolism 2007; 56: 1201.
23. Bayes B, Lauzurica R, Granada ML, et al. Adiponectin and risk of new-onset diabetes mellitus after kidney transplantation. Transplantation 2004; 78: 26.
24. Bayes B, Granada ML, Pastor MC, et al. Obesity, adiponectin and inflammation as predictors of new-onset diabetes mellitus after kidney transplantation. Am J Transplant 2007; 7: 416.
25. Shehab-Eldin W, Shoker A,. Predictors of new onset of diabetes after transplantation in stable renal recipients. Nephron Clin Pract 2008; 110: c1-c9.
26. Hornum M, Jorgensen KA, Hansen JM, et al. New-onset diabetes mellitus after kidney transplantation in Denmark. Clin J Am Soc Nephrol 2010; 5: 709.
27. Frystyk J, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A,. Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia 2005; 48: 1911.
28. Waki H, Yamauchi T, Kamon J, et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 2003; 278: 40352.
29. Laemmli UK,. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680.
30. Cockcroft DW, Gault MH,. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31.
31. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67: 2089.
32. American Diabetes Association. Standards of medical care in diabetes-2007. Diabetes Care 2007; 30 (Suppl. 1): S4-S41.
33. Matsuda M, DeFronzo RA,. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462.
34. Adamczak M, Szotowska M, Chudek J, Karkoszka H, Cierpka L, Wiecek A,. Plasma adiponectin concentration in patients after successful kidney transplantation-a single-center, observational study. Clin Nephrol 2007; 67: 381.
35. Hagen M, Hjelmesaeth J, Jenssen T, Morkrid L, Hartmann A,. A 6-year prospective study on new onset diabetes mellitus, insulin release and insulin sensitivity in renal transplant recipients. Nephrol Dial Transplant 2003; 18: 2154.
36. Pajvani UB, Hawkins M, Combs TP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004; 279: 12152.